Enimmune Corp (安特羅生技) plans to apply to the Taiwan Food and Drug Administration for marketing approval for its enterovirus 71 (EV-71) vaccine next quarter after the treatment passed an interim analysis yesterday.
If approved, it would be the nation’s first vaccine for EV-71, which is a common pathogen that causes polio-like syndromes, and mostly infects infants and children aged five and younger.
Although the firm has developed three EV-71 vaccines in China, the latest treatment would have an advantage in the home market, as it is designed to act against genotype B4 of EV-71, which is more widespread in Taiwan and Vietnam, while Chinese vaccines target genotype C4, Enimmune general manager Vic Chang (張哲瑋) told the Taipei Times by telephone.
The interim analysis was conducted by the firm’s independent data monitoring committee comprised of external experts, Chang said.
The experts monitored vaccinated test subjects for at least six months to see if they developed any allergic reactions, but none of them had severe reactions to the vaccine, barring some mild side-effects, such as inflamed skin, he said.
The overall seroprotection rate for the subjects who were given a single dose in the phase-III clinical trial was about 90 percent, higher than the regulatory minimum, Chang added.
“That means that our vaccines had good efficacy,” Chang added.
Enimmune, a subsidiary of Adimmune Corp (國光生技), has over the past decade focused on researching and developing the EV-71 vaccine.
The firm said that it completed a phase-III randomized, double-blind and placebo-controlled trial in April last year with a 1,266 subjects.
Given that there is no medication for EV-71 infection in Taiwan except for supportive therapies, the vaccine would likely qualify to apply to the agency’s accelerated approval mechanism, in which review would be sped up for treatments that satisfy unmet medical needs and greatly advance treatment, Chang said.
“If everything goes smoothly, we anticipate gaining approval in the fourth quarter. Adimmune would help us manufacture the vaccines,” Chang said.
The government is also expected to consider including the vaccine in the National Health Insurance system, he added.
Meanwhile, Medigen Vaccine Biologics Corp (高端疫苗) said that it would conduct an interim analysis of its EV-71 vaccine later this year after enrolling 3,000 subjects for a phase-III trial in December last year, spokesman Leo Lee (李思賢) said.
“We concentrate on developing the world’s first EV-71 vaccine for protecting children two months to six months old, given all existing EV-71 vaccines would be administered to children older than six months,” Lee said.
NOT ALL GOOD: Analysts warned that other data for last month might be less rosy due to the virus and analysts expect the PMI to contract again next month Chinese factory activity saw surprise growth last month as businesses went back to work following a lengthy shutdown, but analysts said that the economy faces a challenging recovery as external demand has been devastated by the COVID-19 pandemic, while the World Bank said that growth could screech to a halt. China is slowly returning to life after months of tough restrictions aimed at containing the virus, which put millions of people into virtual house arrest and brought economic activity to a near standstill. The strict measures saw a closely watched gauge of manufacturing plunge to its lowest level on record in February,
The output of the global smartphone industry this year is to contract by 7.8 percent on an annual basis as the COVID-19 pandemic ushers in a global recession, Taipei-based market researcher TrendForce Corp (集邦科技) said in a report on Monday. The global production of smartphones is expected to fall to 1.29 billion units, as the pandemic dampens demand for consumer electronics, leading to a decline in shipments across Europe and North America, TrendForce said. With consumers delaying smartphone purchases and thereby lengthening the device replacement cycle, overall prices would suffer a setback that is expected to negatively affect the profitability of smartphone
ELECTRONICS Lite-On delays sale of unit Lite-On Technology Corp (光寶科技) yesterday said it would postpone the sale of its solid-state drives (SSD) business to Kioxia Holdings Corp, formerly known as Toshiba Memory Holdings Corp, due to disruptions amid the COVID-19 pandemic. Last year, the Taiwan-based electronics components supplier struck the deal with the Japanese firm, agreeing to sell the unit for US$165 million. Citing unfinished integration work due to the pandemic, Lite-On has deferred today’s closing date until further notice, adding that the delay would not have a negative effect on the unit’s operations. AUTO PARTS Hiroca approves dividend Automotive interior parts supplier Hiroca
ALL ABOUT STRATEGY: The company is optimistic, saying that its gross margin should increase year-on-year, but it is scaling back on its plans to expand capacity Quang Viet Enterprise Co (QVE, 廣越), which makes down jackets and garments for sportswear and outdoor brands including Adidas AG, yesterday said that revenue might drop 5 to 10 percent annually this year as some customers trimmed orders in response to the COVID-19 pandemic. That would mark its first revenue decline since 2016. Quang Viet posted record-high revenue of NT$16.26 billion (US$537.45 million) last year, up 22 percent from 2018. Down jackets made up 40 percent of it revenue last year. North Face Inc and Patagonia Inc are this year likely to reduce orders by 20 to 30 percent from a
RSS